-
Mashup Score: 1Some Patients With Breast Cancer May Safely Avoid Locoregional Irradiation After Neoadjuvant Chemotherapy - The ASCO Post - 1 month(s) ago
It may be possible for some patients with breast cancer to avoid adjuvant regional nodal irradiation safely, according to the results of the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the 2023 San Antonio Breast Cancer Symposium. 1 These findings particularly apply to patients whose breast cancer conve rted from lymph node–positive to lymph node–negative after neoadjuvant chemotherapy. There was no difference in the 5-year rates of disease recurrence or death among patients who had
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Some Patients With Breast Cancer May Safely Avoid Locoregional Irradiation After Neoadjuvant Chemotherapy - The ASCO Post - 3 month(s) ago
It may be possible for some patients with breast cancer to avoid adjuvant regional nodal irradiation safely, according to the results of the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the 2023 San Antonio Breast Cancer Symposium. 1 These findings particularly apply to patients whose breast cancer conve rted from lymph node–positive to lymph node–negative after neoadjuvant chemotherapy. There was no difference in the 5-year rates of disease recurrence or death among patients who had
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1NATALEE Trial Long-Term Results on Ribociclib Combination Therapy in Early-Stage Breast Cancer - The ASCO Post - 3 month(s) ago
Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone. These results are based on the final invasive disease–free survival analysis of the phase III NATALEE trial, which were pre sented at the 2023 San Antonio Breast Cancer Symposium. 1 The final analysis was performed
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Patients With Advanced Breast Cancer May Gain Multiple Benefits From Exercise as Part of Palliative Care - The ASCO Post - 3 month(s) ago
Although current ASCO guidelines recommend exercise for patients with breast cancer during adjuvant therapy with curative intent, the guidelines state that more study is needed regarding the effects of exercise for patients with metastatic breast cancer. The results of the PREFERABLE-EFFECT trial may change that. 1 PREFERABLE-EFFECT, a randomized, prospective trial conducted in five European countries plus Australia, showed that participating in a supervised, moderate- and high-intensity exercise program
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Reshma Jagsi on Early-Stage Breast Cancer 5-Year Outcomes With Endocrine Therapy and Breast-Conserving Surgery - The ASCO Post - 4 month(s) ago
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, discusses the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients between the ages of 50 and 69 with stage I breast cancer. The regimen demonstrated a low risk of relapse in this population, with a genomic assay used in combination with classic clinical and biological features for treatment selection (Abstract GS02-08). Daniel G. Stover, MD, of The Ohio State University
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Hope Rugo on Advanced Breast Cancer Patient-Reported Outcomes From the CAPItello-291 Trial - The ASCO Post - 4 month(s) ago
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient-reported outcomes from the phase III CAPItello-291 study; the trial centered on adding capivasertib to fulvestrant in patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer. Patients treated with capivasertib and fulvestrant reported maintained health-related quality of life longer than those treated with placebo and
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 28Daniel Stover on Early-Stage Breast Cancer A Biomarker Analysis From the PALLAS Trial - The ASCO Post - 5 month(s) ago
Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage II–III hormone receptor–positive, HER2-negative breast cancer. The genomic subtype PAM50 was defined in the protocol of the PALLAS trial as the primary biomarker for analysis of prediction and prognosis (Abstract
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Senthil Damodaran on Locally Advanced or Metastatic Breast Cancer Phase II Results on Futibatinib - The ASCO Post - 5 month(s) ago
Senthil Damodaran, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses final results from the FOENIX-MBC2 study of the efficacy and safe ty of futibatinib in patients with locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring high-level FGFR1 gene amplification. Futibatinib plus fulvestrant showed antitumor activity in those whose disease had progressed on prior CDK4/6 inhibitors (Abstract RF01-04). Amy Tiersten, MD, of the Icahn School of
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20Daniel Stover on Early-Stage Breast Cancer A Biomarker Analysis From the PALLAS Trial - The ASCO Post - 5 month(s) ago
Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage II–III hormone receptor–positive, HER2-negative breast cancer. The genomic subtype PAM50 was defined in the protocol of the PALLAS trial as the primary biomarker for analysis of prediction and prognosis (Abstract
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20Daniel Stover on Early-Stage Breast Cancer A Biomarker Analysis From the PALLAS Trial - The ASCO Post - 5 month(s) ago
Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage II–III hormone receptor–positive, HER2-negative breast cancer. The genomic subtype PAM50 was defined in the protocol of the PALLAS trial as the primary biomarker for analysis of prediction and prognosis (Abstract
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Some Patients With Breast Cancer May Safely Avoid Locoregional Irradiation After Neoadjuvant Chemotherapy https://t.co/5FWkwOrKOK #bcsm #breastcancer #oncology #SABCS23